Dual 68Ga-DOTATATE and 18F-FDG PET/CT in patients with gastroenteropancreatic neuroendocrine neoplasms: A multicentre, validation study of the NETPET score in 239 patients

#3178

Introduction: PET/CT using 68Ga-labelled somatostatin analogues and 18F-FDG have both been used to image neuroendocrine tumors. Our previously published data proposed the NETPET score to characterise findings on dual PET.

Aim(s): To determine if the NETPET score remains prognostically significant in a large international study.

Materials and methods: We performed a multicentre, retrospective study in patients with unresectable/metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN). Eligible patients had histologically confirmed GEPNEN and underwent 18F-FDG and 68Ga-DOTATATE PET/CT within 90 days of each other. Co-primary endpoints were overall survival (OS) and progression free survival (PFS). The cohort was divided into P1, P2-4 and P5 dual PET groups. OS and PFS by subgroup were compared using the log-rank test.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chan D, Hayes A, Karfis I, Navalkissoor S, Furtado O’Mahony L,

Keywords: NETPET, prognostic biomarker, PET imaging, FDG, 68Ga-DOTATATE,